BRENTWOOD, Tenn. / Jul 19, 2024 / Business Wire / Ardent Health Partners, Inc. (NYSE: ARDT) (f/k/a Ardent Health Partners, LLC and collectively “Ardent Health” or the “Company”), a leading provider of healthcare in growing midsize urban communities across the U.S., today announced the closing of its initial public offering (the “Offering”) of 12,000,000 shares of its common stock sold by the Company at a public offering price of $16 per...Read more
Regular Way Trading on Nasdaq Global Select Market to Begin Tomorrow, June 25 GRAIL is Building and Scaling a Groundbreaking New Cancer Screening Technology MENLO PARK, Calif., June 24, 2024 — GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare company whose mission is to detect cancer early when it can be cured, today announced its spin-off from Illumina (NASDAQ: ILMN) is complete, and GRAIL will be listed and...Read more
TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB® Venture Market (the "OTCQB") under the symbol NRXBF. The OTCQB listing enhances visibility and facilitates trading by US institutional and retail investors. As the sole...Read more
SINGAPORE, April 15, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR), a pioneering Asia-Pacific (APAC) telehealth provider, celebrates its successful initial public offering (IPO) on the Nasdaq stock exchange. This achievement marks MNDR as the first pure-play telehealth company from APAC to list on a major US stock exchange. “This IPO is a significant achievement for MNDR and reflects the surging demand for...Read more
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, with an emphasis on obesity and ocular indications, announced today that the Company has received approval to list its common stock on the Nasdaq Global...Read more
Company's Listing Application Approved by Nasdaq VICTORIA, BC, April 3, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that the Company's common shares have been approved for listing on the Nasdaq...Read more
Auna’s mission is to transform healthcare in Latin America, providing access to a highly integrated offering of quality healthcare services in Spanish-speaking Americas. Auna has built one of Latin America´s largest modern healthcare platforms, with presence in Mexico, Colombia and Peru. 2023 revenues of US$1.05 billion and Adjusted EBITDA of US$223 million, up 58% and 90%, respectively, with Adjusted EBITDA margin expanding to...Read more
LOS ALTOS, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds to Alto from the offering are expected to be approximately $128.6 million before deducting underwriting discounts and commissions and other offering expenses payable by Alto. In...Read more
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE